Prof. Rosenberg took his first degree at the University of Cambridge and subsequently trained in medicine at Guy’s Hospital, London, before obtaining a DPhil (PhD) in molecular and cellular immunology from the University of Oxford.
William has held chairs in Hepatology (Liver Medicine) at the University of Southampton and subsequently at UCL. He has held a variety of leadership roles in universities and in the NHS, including national leadership roles with NIHR, focusing on the interface between the universities, NHS and industry. Professor Rosenberg founded iQur in 2003 and has served as Chief Scientific Officer since then. He was appointed CEO of iQur in February 2007.
Dr. Ramirez trained as a biochemist at Imperial College. He worked at the Novartis Vaccines Institute for Global Health, with the Meningitis B vaccine R&D team. The vaccine would later be successfully launched as Bexsero® in 2013. As a grad student he worked at both the Kennedy Institute of Rheumatology and later at the National Heart and Lung Institute in the UK. His doctoral studies consisted of finding an experimental link between autoimmunity and viral infection. Alex was asked to join the University of Massachusetts Medical School as part of the Infectious Disease department. His project focused on finding the reasons behind low vaccine efficiency in the aged and corrective immuno-modulation strategies using the TIV influenza preclinical model. In 2014 he joined iQur where he served as the Head of Immunology and currently as the Head of Discovery, leading the research efforts to discover new vaccine candidates using the tandem core platform technology.
Founded the company in 2003, and was appointed CEO in 2007.
Bruce joined iQur as non-executive Director in 2005. He has more than 45 years of drug development experience in a wide range of indications that are now on the market. Bruce was formerly R&D Director at Servier (UK), Senior VP of International Development at Neurocrine Biosciences, Inc (US), Chief Scientific Officer at IP2IPO ( IPGroup), and Founder, Chairman and Head of Development for Proximagen Ltd before it was sold to Upsher Smith. He currently acts as a consultant to various pharmaceutical companies . In addition, he has also been a director and European Chairman of the Drug Information Association, and a member of the European ICH Safety Working Party. He is a visiting Professor in Pharmacology at King’s College, London, and has written more than 100 papers involving all aspects of drug development.
Brenda is currently CEO of Calchan Holdings Ltd, a biotech company specialising in medicines for pain and inflammation. She was previously a founder and COO of both Convergence Pharmaceuticals, acquired by Biogen in early 2015, and PowderMed Ltd, acquired by Pfizer in 2006. She is also an NED and independent advisor to a number of life science companies. Earlier in her career Brenda held senior roles within the pharmaceutical industry specialising in project and change management. She is a toxicologist by training and is also a Chartered Director and Fellow of the IOD.
John joined the iQur Board in 2009 and currently works as an independent consultant. He was previously founding CEO and Board Director of Bicycle Therapeutics. Prior to this, he was Vice President and Head of Discovery Biology for the GSK Biopharm CEDD where he was responsible for biology support for biopharma discovery and development. John has a degree in Zoology and PhD in Immunology followed by post-doctoral training at Yale University Medical School. He has been involved in the discovery and development of therapeutic antibodies and vaccines for over 25 years and was the Chairman of the Board for the Edward Jenner Institute for Vaccine Research. John is a frequent contributor to MRC and CR-UK review panels and is currently a member of the MRC-Technology Scientific Advisory Board and Chair of the CR-UK Biotherapeutics Expert Review Panel.
Michael joined the iQur Board to represent the interests of the major shareholders following the Rights Issue in September 2014 and brings with him many years' experience of investing in early stage technology companies.